Simultaneous quantification of erlotinib, gefitinib, and imatinib in human plasma by liquid chromatography tandem mass spectrometry.
作者： A Chahbouni , J C G den Burger , R M Vos , A Sinjewel , A J Wilhelm
DOI: 10.1097/FTD.0B013E3181C05A14
关键词: Tyrosine kinase 、 Erlotinib 、 Chemistry 、 Liquid chromatography–mass spectrometry 、 Calibration curve 、 Mass spectrometry 、 Therapeutic drug monitoring 、 Chromatography 、 Tyrosine-kinase inhibitor 、 Gefitinib
摘要: A quantitative liquid chromatography (LC)-mass spectrometry (MS)/MS method in human plasma was developed and validated for the tyrosine kinase inhibitors erlotinib, gefitinib, imatinib plasma. Pre-treatment of samples achieved by using liquid-liquid extraction D-8 as internal standard. Separation performed on a Waters Alliance 2795 LC system an XBridge RP18 column. The mass spectrometer Micromass equipped with electro spray ionization probe, operating positive mode. calibration curves were linear over concentration range 5 to 3,000; 3,000, 5,000 ng/mL, respectively. intraday interday accuracy ranged from 90% 110% precision within 5%. reported provided necessary linearity, precision, determine clinical research therapeutic drug monitoring.
vumc.nl
sci-hub.se 参考文章(15)
Vinod P Shah, Kamal K Midha, John WA Findlay, Howard M Hill, James D Hulse, Iain J McGilveray, Gordon McKay, Krys J Miller, Rabindra N Patnaik, Mark L Powell, Alfred Tonelli, CT Viswanathan, Avraham Yacobi, Bioanalytical method validation--a revisit with a decade of progress. Pharmaceutical Research. ,vol. 17, pp. 1551- 1557 ,(2000) , 10.1023/A:1007669411738
Ming Zhao, Carol Hartke, Antonio Jimeno, Jing Li, Ping He, Yelena Zabelina, Manuel Hidalgo, Sharyn D. Baker, Specific method for determination of gefitinib in human plasma, mouse plasma and tissues using high performance liquid chromatography coupled to tandem mass spectrometry Journal of Chromatography B. ,vol. 819, pp. 73- 80 ,(2005) , 10.1016/J.JCHROMB.2005.01.027
Stephane Picard, Karine Titier, Gabriel Etienne, Emmanuelle Teilhet, Dominique Ducint, Marie-Agnes Bernard, Regis Lassalle, Gerald Marit, Josy Reiffers, Bernard Begaud, Nicholas Moore, Mathieu Molimard, Francois-Xavier Mahon, Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia Blood. ,vol. 109, pp. 3496- 3499 ,(2007) , 10.1182/BLOOD-2006-07-036012
Petri Salven, Angiogenesis in Lymphoproliferative Disorders Acta Haematologica. ,vol. 106, pp. 184- 189 ,(2001) , 10.1159/000046615
David G. Savage, Karen H. Antman, Imatinib Mesylate — A New Oral Targeted Therapy The New England Journal of Medicine. ,vol. 346, pp. 683- 693 ,(2002) , 10.1056/NEJMRA013339
Darioush Dadgar, Pamela E. Burnett, Issues in evaluation of bioanalytical method selectivity and drug stability Journal of Pharmaceutical and Biomedical Analysis. ,vol. 14, pp. 23- 31 ,(1995) , 10.1016/0731-7085(95)01634-1
B. K. Matuszewski, M. L. Constanzer, C. M. Chavez-Eng, Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Analytical Chemistry. ,vol. 75, pp. 3019- 3030 ,(2003) , 10.1021/AC020361S
Tal Grenader, Maya Gipps, Linda Shavit, Alberto Gabizon, Significant drug interaction: phenytoin toxicity due to erlotinib. Lung Cancer. ,vol. 57, pp. 404- 406 ,(2007) , 10.1016/J.LUNGCAN.2007.02.011
Karine Titier, St??phane Picard, Dominique Ducint, Emmanuelle Teilhet, Nicholas Moore, Patrice Berthaud, Fran??ois-Xavier Mahon, Mathieu Molimard, Quantification of imatinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry Therapeutic Drug Monitoring. ,vol. 27, pp. 634- 640 ,(2005) , 10.1097/01.FTD.0000175973.71140.91
Muthu Veeraputhiran, Mark Sundermeyer, Rhabdomyolysis Resulting from Pharmacologic Interaction Between Erlotinib and Simvastatin Clinical Lung Cancer. ,vol. 9, pp. 232- 234 ,(2008) , 10.3816/CLC.2008.N.036